MDGL — Madrigal Pharmaceuticals, Inc. stock price, charts and financials

QT47Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
514.37
+4.33+0.85%
OverviewShort InterestFilings
MDGLQT47Madrigal Pharmaceuticals, Inc.·NASDAQ
514.37+0.85%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
HALO+0.31%$103.44TECH-0.17%$72.17BMRN+7.41%$68.54ARWR+0.93%$88.47SMMT+4.94%$14.65AXSM+4.11%$221.49EXEL-2.11%$52.93PRAX+1.14%$364.88
Snapshot
Index-P/E-EPS (ttm)-12.89Insider Own15.11%Shs Outstand23.10MPerf Week9.14%
Market Cap11.78BForward P/E76.18EPS next Y6.70Insider Trans-0.46%Shs Float21.53MPerf Month-8.92%
Enterprise Value11.84BPEG114.63EPS next Q-1.25Inst Own105.97%Short Float9.58%Perf Quarter-4.64%
Income-258.07MP/S9.18EPS this Y50.39%Inst Trans-Short Ratio6.34Perf Half Y10.06%
Sales1.28BP/B28.38EPS next Y204.69%ROA-26.12%Short Interest2.06MPerf YTD-12.42%
Book/sh-P/C-EPS next 5Y-ROE-56.65%52W High620.25 -17.07%Perf Year50.85%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-37.02%52W Low336.08 53.05%Perf 3Y156.99%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin91.48%Volatility3.77% 4.21%Perf 5Y484.10%
Dividend TTM-EV/Sales9.22EPS Y/Y TTM41.14%Oper. Margin-25.13%ATR (14)24.46Perf 10Y6397.32%
Dividend Ex-Date-Quick Ratio2.94Sales Y/Y TTM612.78%Profit Margin-25.32%RSI (14)46.69Recom2.17
Dividend Gr. 3/5Y-Current Ratio3.20EPS Q/Q-4.74%SMA20-3.28%Beta-1.02Target Price677.00
Payout0.00%Debt/Eq0.66Sales Q/Q70.89%SMA50-0.94%Rel Volume0.96Prev Close510.04
Employees915LT Debt/Eq0.59EarningsNov 03SMA2000.22%Avg Volume363.00KPrice514.37
IPO DateFeb 06, 2007Option/ShortYes / YesEPS/Sales Surpr.25.72% 3.46%Net Debt/EBITDA-0.18Volume347,529Change0.85%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedWolfe Research$579 → $605
Jul-31-26ReiteratedBarclays$964 → $962
Jul-29-26ReiteratedCanaccord GenuityBuy$578 → $587
Jul-27-26InitiatedWells FargoOverweight$130 → $685
Jun-11-26ReiteratedMorgan Stanley$542
May-13-26ReiteratedTruist SecuritiesBuy$640 → $709
May-07-26ReiteratedCanaccord GenuityBuy$420 → $578
May-07-26ReiteratedEvercore ISI GroupOutperform$405 → $649
Jan-27-26InitiatedBarclaysOverweight$964
Jan-14-26ReiteratedGoldman SachsBuy$375 → $571
Latest News
Aug-06-26
Aug-06-2608:00AM
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conferenceglobenewswire.com
Aug-04-26
Aug-04-2608:11AM
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More247wallst.com
07:46AM
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga
Jul-31-26
Jul-31-2612:36PM
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growthzacks.com
Jul-30-26
Jul-30-2602:05PM
Madrigal Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
11:44AM
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:36AM
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimateszacks.com
07:00AM
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.com
Jul-28-26
Jul-28-2601:35PM
4 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga
Jul-21-26
Jul-21-2604:05PM
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
01:26PM
Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha
Jul-16-26
Jul-16-2608:00AM
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026globenewswire.com
Jul-13-26
Jul-13-2608:03AM
Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark OfficeBenzinga
08:00AM
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolioglobenewswire.com
Jul-10-26
Jul-10-2602:30PM
3 Under-the-Radar Stocks to Buy and Holdfool.com
Company

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Ownership
Total institutional ownership105.97%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,283958180——————
Cost of Goods Sold Incl. D&A109566——————
Gross Profit1,174902174——————
Selling, General and Administrative Excl. Other1,007814435——————
Research and Development490389237——————
Other Operating Expense0-10——————
Operating Income-323-300-498——————
Interest Expense152215——————
Unusual Expense
—————————
Non-Operating Income (Expense)123447——————
Net Income Before Taxes-325-288-466——————
Income Taxes
000——————
Consolidated Net Income-325-288-466——————
Net Income From Continuing Operations-325-288-466——————
Net Income-325-288-466——————
EPS (Recurring)-12.89-12.85-21.90——————
EPS (Basic, Before Extraordinaries)-12.89-12.85-21.90——————
EPS (Diluted)-12.89-12.85-21.90——————
EBITDA-298-264-450——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio11.6313.3736.00——————
Gross Margin91.5094.1596.67——————
Operating Margin-25.18-31.32-276.67——————
Net Margin-25.33-30.06-258.89——————
Shares Outstanding292221——————
Market Capitalization14,91712,8116,480——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$652.77$544.57$436.38$328.19$220.00● Close Price0.00M15.48M30.96M46.44M61.92MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sibold William JohnPresident and CEOJul 20 '26Sale547.302,5001,368,253209,329Jul 20
Sibold William JohnPresident and CEOJul 17 '26Option Exercise0.0050,0000211,829Jul 20
Soergel DavidChief Medical OfficerJun 01 '26Sale495.741,042516,56110,033Jun 01
Levy Richard SDirectorMay 22 '26Sale515.445,6822,928,71622,015May 22
Soergel DavidChief Medical OfficerMay 18 '26Sale515.90844435,42011,075May 18
Dier MardiEVP and CFOMar 06 '26Sale430.871,982853,99112,490Mar 06
Sibold William JohnPresident and CEOMar 06 '26Sale431.941,663718,316161,829Mar 06
Kelley Shannon TGeneral CounselMar 06 '26Sale431.94360155,49812,138Mar 06
Huntsman CaroleChief Commercial OfficerMar 06 '26Sale431.94419180,98312,692Mar 06
Taub RebeccaDirectorMar 06 '26Sale431.94491212,083452,213Mar 06
Dier MardiEVP and CFOMar 02 '26Sale427.211,183505,3899,257Mar 02
Levy Richard SDirectorFeb 23 '26Option Exercise7.362,50018,40027,697Feb 24
Levy Richard SDirectorJan 26 '26Option Exercise16.464,00065,84025,197Jan 26
Sibold William JohnPresident and CEOJan 26 '26Sale492.421,577776,546148,497Jan 26
Huntsman CaroleChief Commercial OfficerJan 26 '26Sale493.78910449,3399,122Jan 26
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.